Owing to a lack of preclinical models of lung cancer with RET rearrangements there have been very few studies examining the efficacy of RET inhibitors and signaling pathways exploited by RET fusions to drive tumorigenesis prior to clinical trials. This evidence concerns the gene RET and lung carcinoma.